Trevaclyn 2 000 mg/ 40 mg приложен едновременно със симвастатин в сравнение със самостоятелното приложение на симвастатин или Trevaclyn 2 000 mg/ 40 mg за 12 седмици значително понижава LDL- C (- 47, 9%, - 37, 0%, - 17, 0%), TG (съответно - 33, 3%, - 14, 7%, - 21, 6%), apo B (съответно - 41, 0%, - 28, 8%, - 17, 1%), и TC (съответно - 29, 6%, - 24, 9%, - 9, 1%), както и LDL- C:
Trevaclyn 2000 mg/ 40 mg administré simultanément avec la simvastatine versus simvastatine seule ou Trevaclyn 2000 mg/ 40 mg seul pendant 12 semaines, a induit des diminutions significatives du LDL-C (47,9%, -37%, -17,0% respectivement), des TG (-33,3%, -14,7%, -21,6% respectivement), des apo B (-1,0%, -28,8%, -17,1% respectivement), et du CT (-29,6%, -24,9%, -9,1% respectivement), ainsi que du rapport LDL-C/ HDL-C (-57,1%, -39,8%, -31,2% respectivement), du non-HDL-C (-45,8%, -33,4%, -18,1% respectivement) et du rapport CT/ HDL-C (-43,0%, -28,0%, - 24,9% respectivement) et augmenté significativement le HDL-C (27,5%, 6,0%, 23,4% respectivement).